SUPPLEMENTARY INFORMATION:

I. Introduction

In 2023, Congress passed the Animal Drug User Fee Amendments of 2023 (Pub. L. 118-15; ADUFA V). The authority for ADUFA V expires September 30, 2028. Without new legislation to reauthorize the program, FDA will no longer be able to collect user fees for future fiscal years to fund the new animal drug review process. Section 740A(d)(1) of the FD&C Act (21 U.S.C. 379j-13(d)(1)) requires that FDA consult with a range of stakeholders in developing recommendations for consideration for the next ADUFA program, including representatives from patient and consumer advocacy groups, veterinary professionals, and scientific and academic experts. To initiate this process of consultation, we announced in the Federal Register of April 17, 2026 (91 FR 20695) that a public meeting is to be held on May 27, 2026, where stakeholders and other members of the public will be given an opportunity to present their views on the reauthorization. The meeting and written comments submitted to the docket will provide critical input as the Agency prepares for reauthorization discussions. Section 740A(d)(3) of the FD&C Act further requires that FDA continue meeting with these stakeholders at least once every 4 months during negotiations with the regulated industry to continue discussions of their views on the reauthorization, including suggested changes to the ADUFA program.

FDA is issuing this Federal Register notice to request that stakeholders—including veterinary professionals, patient and consumer advocacy groups, as well as scientific and academic experts—notify FDA of their intent to participate in the periodic consultation meetings on ADUFA reauthorization. FDA believes that consistent stakeholder representation at these meetings is essential in the reauthorization process. If you wish to participate in this part of the ( printed page 25577) reauthorization process, please designate one or more representatives from your organization who will commit to attending these meetings and preparing for the discussions. Stakeholders who identify themselves through this notice will be included in all future stakeholder discussions while FDA negotiates with the regulated industry. If a stakeholder decides to participate in these meetings at a later time, they may still participate in remaining meetings by notifying FDA (see FOR FURTHER INFORMATION CONTACT ). These stakeholder discussions will satisfy the requirement in section 740A(d)(3) of the FD&C Act.

II. Notification of Intent to Participate in Periodic Stakeholder Consultation Meetings

If you intend to participate in continued periodic stakeholder consultation meetings regarding ADUFA reauthorization, please submit notification by email to: ADUFAreauth@fda.hhs.gov by June 1, 2026. Your email should contain complete contact information for each attendee, including name, title, affiliation, address, email address, telephone number, and notice of any special accommodations required due to a disability ( e.g., Closed Captioning). Stakeholders will receive confirmation and additional information about the first meeting, and subsequent meetings when scheduled, after FDA receives this notification of intent to participate.

91 FR 25576